Oral inhalation of dacomitinib nanocarriers as a therapeutic strategy for non-small cell lung cancer

• Published in: Nanomedicine (London, England) Vol. 19; no. 18-20; p. 1601
• Main Authors: Rongala, Druva Sarika, Patil, Suyash M, Kunda, Nitesh K
• Format: Journal Article
• Language: English
• Published: England 20-08-2024
• Subjects: Administration, Inhalation; Administration, Oral; Antineoplastic Agents - administration & dosage; Antineoplastic Agents - chemistry; Antineoplastic Agents - pharmacology; Antineoplastic Agents - therapeutic use; Carcinoma, Non-Small-Cell Lung - drug therapy; Cell Line, Tumor; Cell Survival - drug effects; Drug Carriers - chemistry; Drug Liberation; Humans; Lactic Acid - chemistry; Lung Neoplasms - drug therapy; Lung Neoplasms - pathology; Nanoparticles - chemistry; Particle Size; Polyglycolic Acid - chemistry; Polylactic Acid-Polyglycolic Acid Copolymer - chemistry; Quinazolinones - administration & dosage; Quinazolinones - chemistry; Quinazolinones - pharmacology; FPF (fine particle fraction); MMAD (mass median aerodynamic diameter); nanoparticles; inhaled therapy; dacomitinib
• ISSN: 1748-6963
• DOI: 10.1080/17435889.2024.2370225

Development of an inhalable nanoformulation of dacomitinib (DMB) encapsulated in poly-(lactic-co-glycolic acid) nanoparticles (NPs) to improve solubility, facilitate direct lung delivery and overcome the systemic adverse effects.
DMB-loaded poly-(lactic-co-glycolic acid) NPs were prepared using solvent evaporation and characterized for particle size, polydispersity index and zeta-potential. The NPs were evaluated for
drug release, aerosolization performance and
efficacy studies.
The NPs showed excellent particle characteristics and displayed a cumulative release of ∼40% in 5 days. The NPs demonstrated a mass median aerodynamic diameter of ∼3 μm and fine particle fraction of ∼80%. Further,
cell culture studies showed improved cytotoxic potential of DMB-loaded NPs compared with free drug.
The study underscores the potential of DMB-loaded NPs as a viable approach for non-small cell lung cancer treatment.